108 related articles for article (PubMed ID: 32987009)
1. SARS-CoV-2 antibody seroprevalence in patients receiving dialysis in the USA.
Flower B; Atchison C
Lancet; 2020 Oct; 396(10259):1308-1309. PubMed ID: 32987009
[No Abstract] [Full Text] [Related]
2. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms.
Billany RE; Selvaskandan H; Adenwalla SF; Hull KL; March DS; Burton JO; Bishop NC; Carr EJ; Beale R; Tang JW; Bird PW; Holmes CW; Baines R; Brunskill NJ; Graham-Brown MPM
Kidney Int; 2021 Jun; 99(6):1492-1494. PubMed ID: 33887316
[No Abstract] [Full Text] [Related]
3. The seroprevalence of SARS-CoV-2 in patients on haemodialysis.
Mahalingasivam V; Tomlinson L
Nat Rev Nephrol; 2021 Apr; 17(4):225-226. PubMed ID: 33230249
[TBL] [Abstract][Full Text] [Related]
4. SARS-COV-2 Infection and Specific Antibody Detection on Health Care Workers from a Military Hospital in Madrid, Spain.
Simón Sacristán M; Ybarra de Villavicencio C; Collazos Blanco A; Mayo Montero ME; Ariñez Fernández MDC; Suárez Prieto A; Zamora Cintas MI; Mateo Maestre M
Curr Microbiol; 2021 Aug; 78(8):2910-2915. PubMed ID: 34156544
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.
Clarke KEN; Jones JM; Deng Y; Nycz E; Lee A; Iachan R; Gundlapalli AV; Hall AJ; MacNeil A
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(17):606-608. PubMed ID: 35482574
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 seroprevalence in the Vatican City State.
Ralli M; Arcangeli A; Soave PM; Voglino MC; De-Giorgio F
Eur J Intern Med; 2021 Apr; 86():98-99. PubMed ID: 33581980
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan.
Yoshihara T; Ito K; Zaitsu M; Chung E; Aoyagi I; Kaji Y; Tsuru T; Yonemura T; Yamaguchi K; Nakayama S; Tanaka Y; Yurino N; Koyanagi H; Matsuki S; Urae R; Irie S
Int J Environ Res Public Health; 2021 Apr; 18(7):. PubMed ID: 33916399
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2.
McConnell D; Hickey C; Bargary N; Trela-Larsen L; Walsh C; Barry M; Adams R
Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33925518
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening.
Pagani G; Conti F; Giacomelli A; Bernacchia D; Rondanin R; Prina A; Scolari V; Gandolfi CE; Castaldi S; Marano G; Ottomano C; Boracchi P; Biganzoli E; Galli M
J Infect; 2020 Dec; 81(6):e10-e12. PubMed ID: 32961253
[TBL] [Abstract][Full Text] [Related]
10. Investigating the utility of COVID-19 antibody testing in end-stage renal disease patients receiving haemodialysis: a cohort study in the United Kingdom.
Wickens O; Chinnadurai R; Mannan F; Svendsen F; Baig MY; Chukwu C; Ali I; Summersgill C; Evans D; Antoine BV; Oxton J; Mairs N; Flanagan E; Oliver R; Kalra PA; Poulikakos D
BMC Nephrol; 2021 Apr; 22(1):154. PubMed ID: 33902482
[TBL] [Abstract][Full Text] [Related]
11. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis.
Galanis P; Vraka I; Fragkou D; Bilali A; Kaitelidou D
J Hosp Infect; 2021 Feb; 108():120-134. PubMed ID: 33212126
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan.
Tanaka A; Yamamoto S; Miyo K; Mizoue T; Maeda K; Sugiura W; Mitsuya H; Sugiyama H; Ohmagari N
J Infect; 2021 Apr; 82(4):e1-e3. PubMed ID: 33524423
[No Abstract] [Full Text] [Related]
14. Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.
Douxfils J; Gillot C; Mullier F; Favresse J
J Infect; 2021 Oct; 83(4):e4-e5. PubMed ID: 34407421
[No Abstract] [Full Text] [Related]
15. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.
Tseng WP; Wu JL; Wu CC; Kuo KT; Lin CH; Chung MY; Lee YF; Yang BJ; Huang CH; Chen SY; Yu CJ; Chen SC; Hsueh PR
Front Immunol; 2021; 12():626609. PubMed ID: 34084161
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
Varona JF; Madurga R; Peñalver F; Abarca E; Almirall C; Cruz M; Ramos E; Castellano Vázquez JM
Int J Epidemiol; 2021 May; 50(2):400-409. PubMed ID: 33434269
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection among Veterans Affairs healthcare system employees suggests higher risk of infection when exposed to SARS-CoV-2 outside the work environment.
Dimcheff DE; Schildhouse RJ; Hausman MS; Vincent BM; Markovitz E; Chensue SW; Deng J; McLeod M; Hagan D; Russell J; Bradley SF
Infect Control Hosp Epidemiol; 2021 Apr; 42(4):392-398. PubMed ID: 32962771
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
[TBL] [Abstract][Full Text] [Related]
20. Potential drawbacks of SARS-CoV-2 seroprevalence surveys.
Lippi G
J Hosp Infect; 2021 Apr; 110():206. PubMed ID: 33358929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
